Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Liquid Biopsy Market 

5.1. COVID-19 Landscape: Liquid Biopsy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Liquid Biopsy Market, By Technology

8.1. Liquid Biopsy Market, by Technology Type, 2023-2032

8.1.1. PCR

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. NGS

8.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Liquid Biopsy Market, By Application

9.1. Liquid Biopsy Market, by Application, 2023-2032

9.1.1. Cancer (Lungs Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Others)

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Non-Cancer

9.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Liquid Biopsy Market, By Circulating Biomarker 

10.1. Liquid Biopsy Market, by Circulating Biomarker, 2023-2032

10.1.1. Circulating Tumor Cells

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Cell-Free DNA

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Circulating Tumor DNA

10.1.3.1. Market Revenue and Forecast (2021-2032)

10.1.4. Extracellular Vesicles

10.1.4.1. Market Revenue and Forecast (2021-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Liquid Biopsy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2021-2032)

11.1.2. Market Revenue and Forecast, by Application (2021-2032)

11.1.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2021-2032)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.1.4.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2021-2032)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.1.5.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2021-2032)

11.2.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2021-2032)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.4.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2021-2032)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.5.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2021-2032)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.6.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2021-2032)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2032)

11.2.7.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2021-2032)

11.3.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2021-2032)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.4.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2021-2032)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.5.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2021-2032)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.6.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2021-2032)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2032)

11.3.7.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2021-2032)

11.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2021-2032)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.4.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2021-2032)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.5.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2021-2032)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.6.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2021-2032)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2032)

11.4.7.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2021-2032)

11.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.5.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2021-2032)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2032)

11.5.4.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2021-2032)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2032)

11.5.5.3. Market Revenue and Forecast, by Circulating Biomarker (2021-2032)

Chapter 12. Company Profiles

12.1. Bio-Rad Laboratories

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Biocept Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Guardant Health

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. F. Hoffmann-La Roche Ltd.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Johnson & Johnson

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Laboratory Corporation of America Holdings

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. MDxHealth SA

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. QIAGEN N.V

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Thermo Fisher Scientific Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms